	US 11,717,505 B2
	Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas
Anne Steinø, Vancouver (CA); Jeffrey A. Bacha, Vancouver (CA); and Dennis M. Brown, Menlo Park, CA (US)
Assigned to Del Mar Pharmaceuticals (BC) Limited, Vancouver (CA)
Appl. No. 16/768,827
Filed by Del Mar Pharmaceuticals (BC) Limited, Vancouver (CA)
PCT Filed Nov. 2, 2018, PCT No. PCT/IB2018/001357 § 371(c)(1), (2) Date Jun. 1, 2020, PCT Pub. No. WO2019/106424, PCT Pub. Date Jun. 6, 2019.
Claims priority of provisional application 62/593,386, filed on Dec. 1, 2017.
Claims priority of provisional application 62/652,702, filed on Apr. 4, 2018.
Prior Publication US 2022/0226277 A1, Jul. 21, 2022
Int. Cl. A61K 31/336 (2006.01); A61P 35/00 (2006.01); A61K 31/047 (2006.01); A61K 31/519 (2006.01)

CPC A61K 31/336 (2013.01) [A61K 31/047 (2013.01); A61K 31/519 (2013.01); A61P 35/00 (2018.01)]

11 Claims

1. A method for treating a diffuse intrinsic pontine glioma (DIPG) in a patient, the method comprising administering a therapeutically effective quantity of an alkylating hexitol derivative to the patient with DIPG.